T
Tobias F. Rinke de Wit
Researcher at University of Amsterdam
Publications - 193
Citations - 19138
Tobias F. Rinke de Wit is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Population & HIV drug resistance. The author has an hindex of 45, co-authored 172 publications receiving 14241 citations. Previous affiliations of Tobias F. Rinke de Wit include University of Alcalá & Foundation Center.
Papers
More filters
Journal ArticleDOI
HIV drug resistance in low-income and middle-income countries
Raph L. Hamers,Raph L. Hamers,Raph L. Hamers,Tobias F. Rinke de Wit,Charles B. Holmes,Charles B. Holmes +5 more
TL;DR: In this article, the authors assess contemporary data on HIV drug resistance in low-income and middle-income countries and their implications for the HIV response, highlighting the potential impact and resistance risks of novel ART strategies and knowledge gaps.
Journal ArticleDOI
Long-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative Study.
TL;DR: This paper conducted 24 interviews and two focus group discussions with a total of 33 health-care providers and expert clients (HIV patients on long-term ART who assist with adherence support of fellow patients).
Journal ArticleDOI
Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa
Seth C Inzaule,Pascale Ondoa,Trevor Peter,Peter Mugyenyi,Wendy S. Stevens,Tobias F. Rinke de Wit,Raph L. Hamers +6 more
TL;DR: The potential role of HIV drug resistance testing for population-based surveillance and individual patient management in sub-Saharan Africa is discussed and the strengths and challenges of promising low-cost technologies and how they can be implemented are reviewed.
Journal ArticleDOI
HIV-HBV coinfection in Southern Africa and the effect of Lamivudine- Versus tenofovir-containing cART on HBV outcomes
Raph L. Hamers,Hans L. Zaaijer,Carole L. Wallis,Margaret Siwale,Prudence Ive,Mariette E. Botes,Kim C. E. Sigaloff,Andy I. M. Hoepelman,Wendy S. Stevens,Tobias F. Rinke de Wit +9 more
TL;DR: Tenofovir-containing first-line cART is preferred for HIV–HBV coinfection in Africa because of a superior resistance profile relative to lamivudine monotherapy.
Journal ArticleDOI
Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa
Seth C Inzaule,Raph L. Hamers,Raph L. Hamers,Marc Noguera-Julian,Marc Noguera-Julian,Maria Casadellà,Mariona Parera,Tobias F. Rinke de Wit,Roger Paredes,Roger Paredes +9 more
TL;DR: Major INSTI resistance mutations were rare and only occurred at low-level resistance detection thresholds, and INSTI-based regimens are expected to be effective across the different major HIV-1 subtypes in the region.